Inclusion Criteria:

          -  All patients with primary, previously untreated, histologically confirmed invasive
             carcinoma of the vulva (any cell type) not amenable to surgical excision. Clinical
             stages T2-T4, N0-3, M0. Hematoxylin & eosin (H & E) stained slide showing
             documentation of the primary invasive cancer is required. All specimens of primary
             tumor require documentation of type

          -  Absolute neutrophil count (ANC) >= 1,500/microliter (performed within 28 days from
             signing consent form)

          -  Platelet count >= 100,000/microliter (performed within 28 days from signing consent
             form)

          -  Creatinine < 2.0 mg/dL (performed within 28 days from signing consent form)

          -  Total bilirubin =< 1.5 times normal (performed within 28 days from signing consent
             form)

          -  Glutamic-oxaloacetic transaminase (SGOT) =< 3 times normal (performed within 28 days
             from signing consent form)

          -  Patients with an Eastern Cooperative Oncology Group/Gynecologic Oncology Group
             (ECOG/GOG) performance status of 0, 1, or 2

          -  Patients with ureteral obstruction must be treated with stent or nephrostomy tube

          -  Patients must be consented within twelve (12) weeks of diagnosis or must be restaged

          -  Patients of childbearing potential must use an effective form of birth control.
             "Patients receiving oral contraceptives should be instructed that alternate or
             additional contraceptive measures should be used during therapy with VIRACEPT."

          -  Confirmed seronegative HIV status within 3 months of signing consent

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

        Exclusion Criteria:

          -  Patients with stage T1N0 disease

          -  Patients who have known metastases to other organs outside the radiation field at the
             time of the original clinical and surgical staging

          -  Patients who have received previous pelvic or abdominal radiation, cytotoxic
             chemotherapy, or previous therapy of any kind for this malignancy

          -  Patients with septicemia or severe infection

          -  Patients who have circumstances that will not permit completion of this study or the
             required follow-up

          -  Patients who are pregnant at the time of diagnosis and do not wish pregnancy
             termination prior to initiation of treatment

          -  Patients with renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal
             transplantation, that would require modification of radiation fields

          -  Patients with other concomitant malignancies (with the exception of non-melanoma skin
             cancer), who had (or have) any evidence of other cancer present within the last 5
             years

          -  Patients with gastrointestinal (GI) tract disease resulting in an inability to take
             oral medication, malabsorption syndrome, a requirement for intravenous (IV)
             alimentation, prior surgical procedures affecting absorption, uncontrolled
             inflammatory GI disease (e.g., Crohn's, ulcerative colitis)

          -  Patients with poorly controlled diabetes mellitus despite medication

          -  Patients taking anti-arrhythmic agents such as amiodarone, quinidine, rifampin, ergot
             derivatives such as ergotamine, St John's wort, human menopausal gonadotropin
             (HMG)-CoA reductase inhibitors such as lovastatin, neuroleptic such as pimozide,
             sedatives such as midazolam and triazolam among other CYP3A4 and CYP2C19 substrates

          -  Patients with phenylketonuria

          -  Patients with estimated glomerular filtration rate (eGFR) < 30